The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—in particular, disease-modifying therapies (DMTs) that can slow the course of the disease. In response, drug developers—from big pharma to small biotech—continue to invest heavily in disease-modifying approaches owing to the tremendous clinical and commercial opportunity in this arena, despite decades of late-phase failures. Although many uncertainties remain about the launch prospects for late-phase anti-amyloid MAbs from Biogen, Eisai, and Roche, key opinion leaders (KOLs) have expressed cautious optimism about these agents and the numerous anti-tau therapies in early- to mid-phase trials. Meanwhile, hope remains for late-phase therapies from Lundbeck/Otsuka, Otsuka/Avanir, and Axsome that are in development for key AD agitation, a key neuropsychiatric symptom. Ultimately, however, the launch of any of these agents is far from guaranteed.
- What are the drivers and constraints in the AD market?
- How large is the treatable AD population by key segments?
- What clinical and commercial impact can be expected from DMTs and neurospsychiatric therapies, should they launch? Which populations will be most affected?
- What are experts’ opinions of the launch prospects for agents in development?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.